Successful validation of protein multiplexing technology platform
Cologne, Germany, June 24, 2015 / B3C newswire / -- AYOXXA Biosystems and Grünenthal, a pain therapeutics specialist, have completed a first research collaboration to validate detection limits for a biomarker based on AYOXXA’s innovative proprietary technology platform. The focus of this study was to analyze an inflammation marker at very low concentrations released from human cells following treatment in cell culture experiments. This new approach aims to develop improved methods for clinical biomarker detection in order to accelerate the development of new drugs for Pain and Inflammation treatment.
Grünenthal provided proprietary samples while AYOXXA contributed in-depth experience in immunoassay development to simultaneously detect multiple targets down to single digit picogramm/mL concentrations. Applications include biological samples with very low initial volume, previously inaccessible by other immunoassays. Protein multiplex analysis for highly valuable samples will open new strategies to improve clinical diagnostic and treatment development optimized for individual patients’ needs.
Michael Rasche, Corporate Vice President Global Commercial operations of AYOXXA Biosystems GmbH expressed: “To collaborate with an important pharma partner such as Grünenthal supports our strategy to become THE protein multiplex testing platform for researchers in academia as well as in the industry. We are currently starting key projects in Europe as well as in the US and are ramping up our capacities to increase our project pipeline short-term."
Dr. Torsten Dunkern, Director and Head of Cellular Biology, Grünenthal GmbH: “The successful cross-validation of AYOXXA´s technology in comparison to homogenous detection methods for analytes used in Grünenthal´s Drug Discovery will facilitate the progression and broader use of its technology into pharmacodynamics studies.”
Dr. Henning Steinhagen, Senior Vice President and Head of Drug Discovery, Grünenthal GmbH added: “AYOXXA’s proprietary technology performed successfully in our hands and we can see a lot of potential future applications.”
About AYOXXA
AYOXXA Biosystems GmbH, an international biotech company based in Cologne (Germany) and Singapore, has developed a proprietary technology platform for multiplex protein analysis. Founded in 2010, AYOXXA is a biotech spin-off company from the National University of Singapore (NUS). Core to the cutting-edge system is a bead-based technology (IEBA) that yields 10,000-fold more data points than a standard 384-well ELISA. The IEBA technology was developed at Associate Professor Dieter Trau’s laboratory at the Department of Biomedical Engineering at NUS. Together with lowest sample volume in the multiplex protein arena, an increased assay robustness, and readout with existing equipment, AYOXXA will bring a paradigm shift to biomedical research, pharmacological screening and preclinical diagnostics development.
About Grünenthal
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.
Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Australia, Latin America and the US. Grünenthal products are sold in more than 155 countries and approx. 5450 employees are working for the Grünenthal Group worldwide. In 2014, Grünenthal achieved revenues of € 1.154 bn.
Contact
AYOXXA Biosystems GmbH
Dr. Marion Lammertz
Marketing Manager Communications
Nattermannallee 1
50829 Köln
+49 (0) 221 222529 41
This email address is being protected from spambots. You need JavaScript enabled to view it.